Southland Equity Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$831K Buy
693
+83
+14% +$84.8K 0.15% 113
2026
Q1
$561K Buy
610
+94
+18% +$95.3K 0.11% 133
2025
Q4
$554K Buy
516
+4
+0.8% +$3.83K 0.11% 130
2025
Q3
$390K Buy
512
+3
+0.6% +$2.23K 0.08% 163
2025
Q2
$397K Sell
509
-10
-2% -$7.77K 0.09% 146
2025
Q1
$428K Sell
519
-17
-3% -$14.1K 0.1% 137
2024
Q4
$414K Hold
536
0.1% 137
2024
Q3
$475K Buy
536
+223
+71% +$200K 0.12% 121
2024
Q2
$283K Sell
313
-247
-44% -$198K 0.08% 164
2024
Q1
$436K Buy
560
+193
+53% +$137K 0.12% 120
2023
Q4
$214K Sell
367
-392
-52% -$229K 0.07% 183
2023
Q3
$408K Hold
759
0.14% 105
2023
Q2
$356K Buy
759
+22
+3% +$9.23K 0.12% 112
2023
Q1
$253K Hold
737
0.1% 152
2022
Q4
$270K Hold
737
0.1% 139
2022
Q3
$238K Hold
737
0.12% 132
2022
Q2
$239K Hold
737
0.11% 136
2022
Q1
$211K Hold
737
0.09% 167
2021
Q4
$204K Buy
+737
New +$187K 0.08% 169

Other funds holding LLY

Southland Equity Partners's LLY Position: Q2 2026 in Review

Southland Equity Partners increased its Eli Lilly (LLY) stake by 14% in Q2 2026, buying an estimated $84.8K and bringing the position to 693 shares worth $831K. The position accounts for 0.15% of the portfolio, ranked #113.

Southland Equity Partners first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. 1,692 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Southland Equity Partners held 693 shares of Eli Lilly worth $831K as of Q2 2026.
  • Southland Equity Partners bought 83 Eli Lilly shares in Q2 2026, an estimated $84.8K.
  • Eli Lilly made up 0.15% of Southland Equity Partners's portfolio in Q2 2026, its #113 holding.
  • Southland Equity Partners first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • 1,692 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Southland Equity Partners's 13F filing for Q2 2026, filed 13 Jul 2026.